I can see how this might be helpful to the wider world, but how does this help Auscann?
They are not the cultivator (Medipharm Labs use bulk biomass)
They are not the extractor (Medipharm Labs is and holds the patents around extraction technique)
They are not the manufacturer of the hard shell capsule (PCI in Melbourne is and hold the patent around this technology)
Even if they show that if you take X mg of CBD, you receive Y mg in your bloodstream, Auscann is not the beneficiary of this and can not charge a margin it. This seems like a zero dollar value proposition.
- Forums
- ASX - By Stock
- AC8
- Ann: AusCann Investor Webinar Recording
Ann: AusCann Investor Webinar Recording, page-11
-
-
- There are more pages in this discussion • 81 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AC8 (ASX) to my watchlist
(20min delay)
|
|||||
Last
4.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $17.62M |
Open | High | Low | Value | Volume |
0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Featured News
AC8 (ASX) Chart |
Day chart unavailable